Glucophage
Glucophage Price range: $ 28,00 through $ 97,00
Back to products
Glucotrol XL
Glucotrol XL Price range: $ 14,00 through $ 170,00

Glucophage Trio

Price range: $ 96,00 through $ 187,00

Glucophage Trio is a comprehensive oral medication specifically designed to support adults in managing type 2 diabetes. This powerful formula combines three active ingredients to effectively lower blood glucose levels and maintain steady glycemic control. By optimizing how the body processes sugar and improving insulin sensitivity, the medication helps stabilize daily metabolic function. The triple-action approach streamlines your wellness routine by delivering multiple therapeutic benefits in a single, convenient tablet. Regular use of Glucophage Trio serves as a vital component in a long-term strategy to prevent health complications related to high blood sugar.

Active substance: Glimepiride, metformin, Voglibose
SKU: Glucophage Trio Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Glucophage Trio: Information for Patients and Caregivers

Glucophage Trio belongs to a class of combination oral antihyperglycemic medications designed for blood glucose management in type 2 diabetes mellitus. This multi-agent formulation works through complementary physiological pathways to assist in achieving glycemic control when monotherapy or dual therapy provides inadequate blood sugar regulation.

In the United States, combination antihyperglycemic therapies are classified as prescription medications and are dispensed strictly in accordance with applicable federal and state regulations. Treatment must be initiated and monitored by a qualified healthcare professional based on individual clinical evaluations and laboratory findings.

Attribute Details
Drug name Glucophage Trio
Therapeutic class Antihyperglycemic Combination Agents
Dosage form Oral tablet
Route of administration Oral
Primary purpose Glycemic control in Type 2 Diabetes Mellitus
Prescription status Prescription (Rx) only

How the drug works

The mechanism of action of Glucophage Trio relies on the distinct pharmacodynamic profiles of its active components. The biguanide constituent, metformin, decreases hepatic glucose production by inhibiting gluconeogenesis, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Complementary components within the combination target additional metabolic pathways, such as stimulating endogenous insulin secretion from pancreatic beta cells or promoting urinary glucose excretion through inhibition of renal glucose reabsorption. By combining these distinct mechanisms of action into a single therapeutic regimen, the medication addresses multiple pathophysiological defects inherent in type 2 diabetes, resulting in reduced fasting and postprandial plasma glucose concentration levels.

Main uses

Glucophage Trio is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is prescribed when blood glucose levels remain inadequately controlled on single or dual oral antidiabetic agents. The medication is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it requires functioning endogenous insulin secretion to achieve its full therapeutic effect. Any potential off-label use, such as insulin resistance management in polycystic ovary syndrome (PCOS), is not an FDA-approved indication for this combination product and requires explicit clinical authorization and specialized medical oversight.

Dosing schedule

The dosage of Glucophage Trio is determined individually by the prescribing provider based on current blood glucose measurements, hemoglobin A1c (HbA1c) targets, and patient tolerability. Tablets must be administered orally with meals to minimize gastrointestinal adverse effects commonly associated with biguanide therapy. Therapy is typically initiated at lower target doses and titrated gradually depending on therapeutic response and renal function metrics. Patients must swallow the tablets whole with a full glass of water and avoid crushing, chewing, or splitting the medication unless explicitly instructed by a clinician. Regular monitoring of renal parameters is mandatory during dosage titration.

What happens in the body

Following oral administration, the metformin component of the combination is absorbed primarily from the small intestine, achieving peak plasma concentration within 2 to 3 hours. Its absolute oral bioavailability under fasting conditions is approximately 50% to 60%. Metformin does not undergo hepatic metabolism and does not bind to plasma proteins; it is eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion, exhibiting a plasma elimination half-life of roughly 6.2 hours. Co-administered active ingredients undergo distinct metabolic pathways: secondary components may undergo hepatic metabolism via cytochrome P450 pathways or be cleared via renal and biliary routes, depending on their specific molecular structure and pharmacokinetics.

Compatibility with other medicines

Drug interactions with Glucophage Trio can significantly alter therapeutic efficacy or increase the risk of severe adverse events. Intravenous administration of iodinated contrast media during radiological procedures can induce acute renal failure, leading to toxic accumulation of metformin and an increased risk of lactic acidosis. Cationic medications cleared by renal tubular secretion (such as ranitidine, cimetidine, triamterene, and trimethoprim) compete for common renal transport systems, potentially increasing systemic exposure to the drug. Additionally, drugs that induce hyperglycemia, including corticosteroids, thiazide diuretics, oral contraceptives, and sympathomimetics, can impair glycemic control and necessitate adjustment of the antidiabetic dosage.

Adverse reactions

Adverse reactions associated with Glucophage Trio range from mild, transient gastrointestinal effects to serious systemic complications. Gastrointestinal symptoms represent the most common side effects and include diarrhea, nausea, vomiting, flatulence, abdominal bloating, and anorexia; these effects often diminish with continued therapy or administration with food. Hypoglycemia may occur, particularly if the combination contains an insulin secretagogue or if used in conjunction with exogenous insulin or strenuous physical exercise. Long-term administration of the metformin component can cause a decrease in serum vitamin B12 absorption, which may lead to megaloblastic anemia or peripheral neuropathy in susceptible individuals.

Important precautions

A primary safety concern associated with biguanide-containing therapies is lactic acidosis, a rare but life-threatening metabolic emergency characterized by elevated blood lactate levels. Treatment is contraindicated in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] below 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, acute heart failure, or conditions associated with hypoxemia or tissue hypoperfusion. Renal function must be assessed prior to initiating treatment and evaluated at least annually thereafter. In elderly patients or those with mild-to-moderate renal impairment, more frequent monitoring of eGFR and renal parameters is clinically required.

What to avoid while taking it

Patients taking Glucophage Trio must avoid excessive acute or chronic consumption of alcohol. Ethanol potentiates the effect of biguanides on lactate metabolism, significantly heightening the risk of developing severe lactic acidosis, while simultaneously increasing the likelihood of unpredictable hypoglycemia. Additionally, patients should avoid dehydration, severe caloric restriction, or prolonged fasting, as these conditions alter electrolyte balances and increase susceptibility to metabolic complications. Taking the medication consistently with meals helps minimize acute gastrointestinal distress.

If you skip a dose

If a dose of Glucophage Trio is missed, it should be taken as soon as remembered during the same day with a meal. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular dosing schedule resumed. Patients must never take two doses simultaneously or consume extra tablets to compensate for a skipped dose, as doubling the medication significantly elevates the risk of severe gastrointestinal discomfort and acute hypoglycemia.

Red flags

Immediate emergency medical care is required if a patient displays signs or symptoms indicative of lactic acidosis or severe adverse reactions. Clinical warning signs requiring urgent emergency evaluation include:

  • Severe malaise, unusual muscle pain, or unexplained general weakness
  • Difficulty breathing, rapid deep respiration, or shortness of breath
  • Severe, sudden abdominal pain accompanied by nausea and persistent vomiting
  • Signs of severe hypoglycemia, including confusion, dizziness, seizures, or loss of consciousness
  • Symptoms of a severe hypersensitivity reaction, such as swelling of the face, lips, tongue, or throat, or widespread rash

Common questions

Can Glucophage Trio cause low blood sugar (hypoglycemia)?

Yes, hypoglycemia can occur during treatment, particularly if the combination includes an insulin secretagogue or if it is used alongside other antidiabetic agents, such as insulin or sulfonylureas. Hypoglycemia risk also increases during prolonged exercise, reduced caloric intake, or alcohol consumption. Patients should know how to recognize signs of low blood sugar, such as sweating, tremors, rapid heartbeat, and confusion.

What precautions are necessary before undergoing surgical or imaging procedures?

Glucophage Trio must generally be discontinued temporarily prior to or at the time of procedures involving iodinated contrast dyes or elective surgery requiring general anesthesia. Because contrast media can temporarily impair kidney function and lead to drug accumulation, treatment is typically paused and resumed only 48 hours after the procedure, provided renal function has been re-evaluated and confirmed stable.

Is Glucophage Trio prescribed for weight loss?

Glucophage Trio is not approved by the FDA as a primary weight-loss medication. While the metformin component is considered weight-neutral or may lead to modest weight reduction in some individuals through metabolic effects, the primary goal of this formulation is blood glucose stabilization in type 2 diabetes mellitus.

How does kidney function affect the safety of this medication?

Because the metformin component is excreted unchanged by the kidneys, reduced renal clearance leads to drug accumulation and an increased risk of lactic acidosis. Routine blood tests to measure eGFR are mandatory before starting therapy and at regular intervals during treatment to ensure the kidneys are functioning adequately to clear the medication.

Can Glucophage Trio be taken during pregnancy or breastfeeding?

Glucophage Trio is generally not recommended for use during pregnancy or lactation. Adequate blood glucose control during pregnancy is critical, and insulin is typically preferred over oral antidiabetic combination products to maintain glycemic targets. Female patients who are pregnant, planning to become pregnant, or breastfeeding must consult their healthcare provider to adjust their treatment regimen appropriately.

In accordance with FDA guidelines.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

1 mg + 0.2 mg + 500 mg

Package

60 tabs

,

90 tabs

,

120 tabs

Ενεργός Ουσία

,

,